RECURSION PHARMACEUTICALS, INC.

RXRX

Explore Our Financial Data > Companies > RECURSION PHARMACEUTICALS, INC.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	RXRX
CIK	0001601830
SIC	2836
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Biological Products, Except Diagnostic Substances

Contact

Address	41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
Website	recursion.com
Phone	(385) 269-0203
CEO	Chistopher C. Gibson
Employees	400

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$59.79 million
Pre-Tax Income	$-575.28 million
Net Income	$-574.78 million
Net Income to Common	$-574.78 million
EPS	$-1.80

View All

Balance Sheet

Cash	$500.45 million
Assets	$1.31 billion
Liabilities	$371.29 million
Common Equity	$933.95 million
Liabilities & Equity	$1.31 billion

View All

Cash Flow Statement

Net Income	$-574.78 million
Cash From Operating Activities	$-388.83 million
Cash From Investing Activities	$259.44 million
Cash From Financing Activities	$330.75 million
Change in Cash	$203.01 million

View All

Calculations

NOPAT	$-401.82 million
EBITDA	$-526.83 million
Price to Earnings	N/A
Price to Book	$2.79
ROE	-86.10%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Recursion Pharmaceuticals (RXRX) Sees 14% Price Surge Over Last Month

Recursion Pharmaceuticals (RXRX) recently experienced a share price increase of 14% over the last month. This upward movement comes amid a flat broader market trend in the last week and coincides with a stable market performance rising 15% over the past year. While the latest key developments surrounding the company have not been provided, any events from the last month would either reinforce or counteract the broader market dynamics. Despite market predictions anticipating 15% annual...

Article Link

Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.52, indicating a +2.41% shift from the previous trading day.

Article Link

Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock

RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.

Article Link

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.

Article Link

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.72, marking a +2.24% move from the previous day.

Article Link